Publications by authors named "Kazuki Tanimura"
Article Synopsis
- Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) has a high treatment failure rate and is characterized by gene fusions, particularly involving the PDGFRB gene.
- Researchers identified a new PDGFRB fusion gene, NRIP1::PDGFRB, in a pediatric ALL patient, which encodes a protein with the kinase domain of PDGFRB but lacks the partner peptide.
- The study confirmed that NRIP1::PDGFRB has oncogenic potential and can be effectively targeted by various ABL1-specific inhibitors like imatinib and dasatinib, highlighting a novel fusion gene pattern in Ph-like ALL.
Article Synopsis
- This study aimed to identify genetic changes and potential treatment targets in advanced pediatric solid tumors through genomic profiling.
- Conducted at the National Cancer Center in Japan, it analyzed tumor and blood samples from 142 pediatric patients with recurrent or refractory cancer, finding significant genetic alterations in 59% of those evaluable.
- The research highlights the importance of genomic medicine in understanding tumor biology and developing new therapies, while also noting challenges in accessibility and a limited number of actionable treatment options.
Background: The prognosis of relapsed or refractory osteosarcoma remains poor. Recent reports have stated that molecular targeting agents, including multiple tyrosine kinase inhibitors (MTKIs), are effective against adult osteosarcoma. To determine the safety and efficacy of MTKI therapy in children, adolescents and young adults (AYAs), we conducted a retrospective study on adverse events and treatment outcomes.
View Article and Find Full Text PDFArticle Synopsis
- - Gemcitabine and Docetaxel (GEM/DTX) are common chemotherapy drugs used for soft tissue sarcomas but their effectiveness against malignant rhabdoid tumors (MRTs) is not well-studied.
- - In a small study, GEM/DTX was used as salvage therapy for relapsed MRTs, showing partial responses in 3 out of 4 patients, including two with malignant rhabdoid tumors of the kidney.
- - While GEM/DTX shows potential for treating resistant MRTs, there are specific side effects that require careful monitoring, such as localized edema and pleural effusion.
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) reported to show a higher efficacy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) than other TKIs. However, few studies describe ponatinib for pediatric Ph+ALL; therefore, the efficacy, safety, and optimal dosage have not been determined. Here, we report a 3-year-old girl with Ph+ALL treated by a ponatinib-containing regimen with therapeutic drug monitoring in the plasma and cerebrospinal fluid (CSF).
View Article and Find Full Text PDFAn 18-year-old female patinet with Ebstein anomaly underwent surgical repair of scoliosis under total intravenous anesthesia. In addtition to normal monitors, we used transesophageal echocardiography (TEE) and EV1000 (Edwards Lifesciences, Irvine, USA), which show stroke volume variation and stroke volume index simultaneously in a rectangular coordinates. TEE detected reversal of intracardiac shunt which caused SpO2 decrease during fixing screws at thoracic vertebrae, then manual ventilation with oxygen unproved SpO2.
View Article and Find Full Text PDF